OLMA Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Olema Pharmaceuticals's net margin of -49.65%. Olema Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Olema Pharmaceuticals has a consensus price target of $26.00, signalling upside risk potential of 501.85%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 37.1%. Given that Olema Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Olema Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Olema Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

Olema Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Olema Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Olema Pharmaceuticals's net income of -$33.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Olema Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of -- compared to Olema Pharmaceuticals's net margin of -30.91%. Olema Pharmaceuticals's return on equity of -- beat PTC Therapeutics's return on equity of --.

Olema Pharmaceuticals has a consensus price target of $26.00, signalling upside risk potential of 501.85%. On the other hand PTC Therapeutics has an analysts' consensus of $64.93 which suggests that it could grow by 13.85%. Given that Olema Pharmaceuticals has higher upside potential than PTC Therapeutics, analysts believe Olema Pharmaceuticals is more attractive than PTC Therapeutics.

Olema Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.660, suggesting its less volatile than the S&P 500 by 34.007%.

Olema Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Olema Pharmaceuticals quarterly revenues are --, which are smaller than PTC Therapeutics quarterly revenues of $213.2M. Olema Pharmaceuticals's net income of -$33.6M is higher than PTC Therapeutics's net income of -$65.9M. Notably, Olema Pharmaceuticals's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals is -- versus 5.43x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Olema Pharmaceuticals's net margin of -2357.27%. Olema Pharmaceuticals's return on equity of -- beat Palatin Technologies's return on equity of --.

Olema Pharmaceuticals has a consensus price target of $26.00, signalling upside risk potential of 501.85%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 829.74%. Given that Palatin Technologies has higher upside potential than Olema Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Olema Pharmaceuticals.

Olema Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

Olema Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Olema Pharmaceuticals quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Olema Pharmaceuticals's net income of -$33.6M is lower than Palatin Technologies's net income of -$2.4M. Notably, Olema Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Olema Pharmaceuticals's net margin of --. Olema Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

Olema Pharmaceuticals has a consensus price target of $26.00, signalling upside risk potential of 501.85%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 398.75%. Given that Olema Pharmaceuticals has higher upside potential than Theriva Biologics, analysts believe Olema Pharmaceuticals is more attractive than Theriva Biologics.

Olema Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

Olema Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Olema Pharmaceuticals quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Olema Pharmaceuticals's net income of -$33.6M is lower than Theriva Biologics's net income of -$4.4M. Notably, Olema Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.